Citryll Appoints Sjoerd van Gorp as Director of Operations

Oss, The Netherlands, October 4, 2021 — Citryll, a clinical stage pioneer in the NETosis space focused on the development of proprietary first-in-class therapeutic antibody drugs, today announced that it has appointed Sjoerd van Gorp, PhD as Director of Operations  to strengthen Citryll’s Management Team. Sjoerd will join the company’s leadership to strengthen and develop the corporate and operational strategy for the development of its anti-citrullinated mAb assets and technology. Sjoerd will work closely with key development partners to expand the therapeutic utilities of CIT-013, its clinical development candidate and derivatives. Sjoerd will report to CEO Helmuth van Es.

Sjoerd van Gorp has 12 years of experience in the life sciences and healthcare sector in various roles within translational academic research, investment banking and venture capital. Most recently Sjoerd was Senior Investment Manager at BOM Brabant Ventures where he was instrumental in fundraising and strategic support of numerous early-stage life sciences companies. Prior to joining BOM, Sjoerd gained experience as an equity analyst at Kempen & Co, a life sciences investment bank in the Netherlands, where he covered public European biotech and medtech companies and was involved in capital market transactions.
In addition, he has worked on translational academic research projects at the Image Sciences Institute at the University Medical Center Utrecht, the Netherlands and Yale University, USA. Sjoerd will bring a complementary set of skills to the management team that will enable Citryll to assess additional strategic options to unlock the full potential of CIT-013 and enable treatment for a growing list of diseases that are associated with Neutrophil Extracellular Trap (NET) biology.
“We warmly welcome Sjoerd to the company and are pleased to have him join the management team. His proven track record in company building, fundraising and stakeholder management, combined with a broad perspective on innovation and value creation in drug development, will strengthen and broaden the scope of our current activities to support the progress of Citryll’s development programs.”, said CEO and executive board member Helmuth van Es.
“Citryll is successfully pioneering the Netosis space with a first-in class therapeutic antibody and is rapidly moving towards the first clinical validation of a NET antagonist in therapeutic areas with a high unmet medical need. CIT-013 holds great promise for many patients and I’m committed and excited to work with the team to unlock the full potential of the current pipeline for all stakeholders. “, said Sjoerd van Gorp.